0001192482-15-000164.txt : 20150506 0001192482-15-000164.hdr.sgml : 20150506 20150506161350 ACCESSION NUMBER: 0001192482-15-000164 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20150506 FILED AS OF DATE: 20150506 DATE AS OF CHANGE: 20150506 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC CENTRAL INDEX KEY: 0001267565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 DEDHAM STREET, SUITE 800 CITY: CANTON STATE: MA ZIP: 02021 BUSINESS PHONE: 781-713-3699 MAIL ADDRESS: STREET 1: 780 DEDHAM STREET, SUITE 800 CITY: CANTON STATE: MA ZIP: 02021 FORMER COMPANY: FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC DATE OF NAME CHANGE: 20031020 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hirsch David CENTRAL INDEX KEY: 0001619884 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37372 FILM NUMBER: 15837137 MAIL ADDRESS: STREET 1: C/O LONGITUDE CAPITAL PARTNERS, LLC STREET 2: 800 EL CAMINO REAL, SUITE 220 CITY: MENLO PARK STATE: CA ZIP: 94025 3 1 edgar.xml PRIMARY DOCUMENT X0206 3 2015-05-06 0 0001267565 COLLEGIUM PHARMACEUTICAL, INC COLL 0001619884 Hirsch David C/O LONGITUDE CAPITAL PARTNERS, LLC 800 EL CAMINO REAL, STE. 220 MENLO PARK CA 94024 1 0 1 0 Series B Convertible Preferred Stock Common Stock 1860570 I By: Longitude Venture Partners, L.P. Series B Convertible Preferred Stock Common Stock 37290 I By: Longitude Capital Associates, L.P. Series C Convertible Preferred Stock Common Stock 458102 I By: Longitude Venture Partners, L.P. Series C Convertible Preferred Stock Common Stock 9182 I By: Longitude Capital Associates, L.P. Series D Convertible Preferred Stock Common Stock 731214 I By: Longitude Venture Partners, L.P. Series D Convertible Preferred Stock Common Stock 14656 I By: Longitude Capital Associates, L.P. All series of Convertible Preferred Stock will automatically convert into Collegium Pharmaceutical, Inc. common stock on a 1-for-6.9 basis immediately prior to the closing of the initial public offering and have no expiration date. The shares are held by Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P. (collectively, the "Longitude Funds"). Longitude Capital Partners, LLC is the general partner of the Longitude Funds and may be deemed to have sole voting investment and dispositive power over the shares held by the Longitude Funds. Patrick G. Enright and Juliet Tammenoms Bakker are managing members of Longitude Capital Partners, LLC and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by the reporting persons. David Hirsch is a member of Longitude Capital Partners, LLC. Dr. Hirsch disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. /s/ Paul Brannelly as Attorney-In-Fact For David Hirsch 2015-05-06 EX-24 2 poahirsch.htm POA

                                POWER OF ATTORNEY



 Know all by these presents, that the undersigned hereby constitutes

and appoints each of Paul Brannelly and Michael T. Heffernan, with full power

to act singly, as the undersigned's true and lawful attorney-in-fact with full

power of substitution to:



 (1)  execute for and on behalf of the undersigned, in the

undersigned's capacity as an officer and/or director and/or beneficial owner

of Collegium Pharmaceutical Inc.  (the "Company"), Form ID Application,

Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act

of 1934, as amended and the rules thereunder;



 (2)  do and perform any and all acts for and on behalf of the

undersigned which may be necessary or desirable to complete and execute

any such Form ID Application, Forms 3, 4 or 5, complete and execute any

amendment or amendments thereto and timely file such forms with the

United States Securities and Exchange Commission and any stock exchange

or similar authority; and



 (3)  take any other action of any type whatsoever in connection

with the foregoing which, in the opinion of such attorney-in-fact, may be of

benefit to, in the best interest of, or legally required by, the undersigned,

it being understood that the documents executed by such attorney-in-fact

on behalf of the undersigned pursuant to this Power of Attorney shall be in

such form and shall contain such terms and conditions as such attorney-in-fact

may approve in such attorney-in-fact's discretion.



 The undersigned hereby grants to the attorney-in-fact full power and

authority to do and perform any and every act and thing whatsoever requisite,

necessary or proper to be done in the exercise of any of the rights and powers

herein granted, as fully to all intents and purposes as the undersigned might

or could do if personally present, with full power of substitution or revocation,

hereby ratifying and confirming all that such attorney-in-fact, or such

attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be

done by virtue of this power of attorney and the rights and powers herein

granted.



 This power of attorney shall remain in full force and effect until

revoked by the undersigned in a signed writing delivered to the attorney-in-fact.



 IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney

to be executed as of the 23rd day of April, 2015.







     /s/David Hirsch, M.D., Ph.D.

     Name: David Hirsch, M.D., Ph.D.

                                        Title: Director